Postlude 262 23. Polak TB, van Rosmalen J, Uyl - de Groot CA, Rosmalen J, Uyl – de Groot CA. Expanded access as a source of real-world data: An overview of FDA and EMA approvals. Br J Clin Pharmacol. 2020;86(9):1819-1826. doi:10.1111/bcp.14284 24. Su L, Chen X, Zhang J, Yan F. Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials. JCO Precis Oncol. 2022;(6). doi:10.1200/po.21.00394 25. Real-world data from expanded access programmes: statistical and political challenges. Health~Holland. Accessed May 5, 2023. https://www.health-holland.com/ project/2020/2020/real-world-data-expandedaccess-programmes-statistical-and-politicalchallenges 26. Singer ME, Hack DC, Hanley DF. The power of public–private partnership in medical technology innovation: Lessons from the development of FDA-cleared medical devices for assessment of concussion. J Clin Transl Sci. 2022;6(1):e42. doi:10.1017/cts.2022.373 27. Wetenschap van geldschieters | Het Financieele Dagblad. Wetenschap van geldschieters | Het Financieele Dagblad. Accessed May 5, 2023. https://specials.fd.nl/samenleving/1467555/ wetenschap-van-geldschieters 28. Boers M. Public/private partnerships, at what price? Ann Rheum Dis. 2022;81(10):e211-e211. doi:10.1136/annrheumdis-2020-217664 29. Monaghan BJ, Malek AM, Simson H. PublicPrivate Partnerships in Healthcare: Criteria for Success. Healthc Manage Forum. 2001;14(4):4449. doi:10.1016/S0840-4704(10)60424-3 30. Polak TB, Cucchi DGJ, van Rosmalen J, Uyl-de Groot CA. The DRUG Access Protocol: access inequality and European harmonisation. Lancet Oncol. 2022;23(5):e202-e202. doi:10.1016/ S1470-2045(22)00098-5 31. Hilal T, Sonbol MB, Prasad V. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. JAMA Oncol. 2019;5(6):887-887. doi:10.1001/ jamaoncol.2019.0167 32. Rubin R. More Diversity in Clinical Trials. JAMA. 2022;327(19):1860. doi:10.1001/jama.2022.7172 33. DreyerNA.AdvancingaFrameworkforRegulatory Use of Real-World Evidence: When Real Is Reliable. Ther Innov Regul Sci. 2018;52(3):362368. doi:10.1177/2168479018763591 34. Eichler HG, Bloechl-Daum B, Bauer P, et al. “Threshold-crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials? Clin Pharmacol Ther. 2016;100(6):699-712. doi:10.1002/cpt.515 35. Liu M, Chen Z, Dai MY, et al. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19. Transfusion (Paris). 2020;60(10):2210-2216. 36. Wendel S, Land K, Devine DV, et al. Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. Vox Sang. 2021;116(8):872-879. doi:10.1111/ vox.13096 37. Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021;384(11):1015-1027. doi:10.1056/ NEJMoa2031893 38. Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19. JAMA. 2021;325(12):1185-1185. doi:10.1001/ jama.2021.2747 39. Bunnik EM, Aarts N, van de Vathorst S. The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications. J Pharm Policy Pract. 2017;10(1):10-10. doi:10.1186/ s40545-017-0100-3 40. Bunnik EM, Aarts N, van de Vathorst S. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs. Health Policy Amst Neth. 2018;122(9):977-983. doi:10.1016/j. healthpol.2018.06.005 41. Bibbins-Domingo K, Helman A, Dzau VJ. The Imperative for Diversity and Inclusion in Clinical Trials and Health Research Participation. JAMA. 2022;327(23):2283. doi:10.1001/ jama.2022.9083
RkJQdWJsaXNoZXIy MTk4NDMw